Breaking News

PharmaCell Wins ImmunoCellular Contract for Phase III Program

Will perform tech transfer and support clinical trial for ICT-107

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PharmaCell B.V. has entered an agreement with ImmunoCellular Therapeutics Ltd. to support its Phase III trial in Europe for ICT-107, a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the most common and deadliest forms of brain cancer.   PharmaCell will perform a technology transfer from its U.S.-based contract manufacturing partner to its newly acquired Geleen facility in The Netherlands, and support the subsequent clinical trial for ICT-107.   Andrew Gengos, chief ex...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters